Related Experiment Video
Updated: Jan 2, 2026
Evaluation of Lung Metastasis in Mouse Mammary Tumor Models by Quantitative Real-time PCR
Published on: January 29, 2016
Pilot evaluation of a HER2 testing in non-small-cell lung cancer
Katsuyuki Hotta1,2, Hiroyuki Yanai3, Kadoaki Ohashi4
1Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan khotta@okayama-u.ac.jp.
Aims:
HER2-positivity pattern in the specimens of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) has been hardly reported in non-small-cell lung cancer (NSCLC).
Methods:
We evaluated the characteristics of HER2-positivity pattern in formalin-fixed paraffin-embedded samples using IHC and FISH in 15 patients enrolled in a larger prospective cohort study to survey a HER2-positive NSCLC.
Results:
As for the immunostaining pattern, most specimens (79%) demonstrated incomplete or mixed-typed membranous immunoreactivity with heterogeneity, resembling that observed in gastric cancer rather than breast cancer. Concordance between IHC-positivity and FISH-positivity was 87.5% according to the criteria for breast cancer scoring system. On application of the gastric cancer scoring system to the examined tumours, the IHC score increased in the seven (43.8%) specimens, and the concordance between IHC positivity and FISH positivity rose to 93.8%.
Conclusions:
In our pilot series, the pattern of IHC reactivity closely resembled that observed in gastric cancer rather than breast cancer.
Trial Registration Number:
000017003.
More Related Videos
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023